Renal protective effects of resveratrol

Oxidative Medicine and Cellular Longevity

Volumn , Issue , 2013, Pages

  Kitada, Munehiro ^a   Koya, Daisuke ^a  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLATION; ANTIOXIDANTS; CELL DEATH; CHEMICAL ACTIVATION; POLYPHENOLIC COMPOUNDS; PROTEINS; RESVERATROL; SCAVENGING;

ANTIOXIDATIVE PROPERTY; CARDIO-VASCULAR DISEASE; DIABETIC NEPHROPATHY; ISCHEMIA-REPERFUSION INJURY; MITOCHONDRIAL BIOGENESIS; MULTIPLE CELLULAR FUNCTIONS; REACTIVE OXYGEN SPECIES; UNILATERAL URETERAL OBSTRUCTIONS;

DISEASES;

ALDOSTERONE; REACTIVE OXYGEN METABOLITE; RESVERATROL; SIRTUIN 1;

APOPTOSIS; AUTOPHAGY; BIOGENESIS; CALORIC RESTRICTION; CELL FUNCTION; CELL STRESS; DEACETYLATION; DIABETIC NEPHROPATHY; DRUG EFFECT; DRUG MECHANISM; GLUCOSE METABOLISM; KIDNEY INJURY; LIFESPAN; LIPID METABOLISM; NONHUMAN; PROTEIN TARGETING; RENAL PROTECTION; REPERFUSION INJURY; REVIEW; SEPSIS; URETER OBSTRUCTION;

EID: 84893832190     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2013/568093     Document Type: Review

References (69)

1. Levin A., Stevens P. E., Summary of KDIGO guideline: behind the scenes, need for guidance, and a framework for moving forward. Kidney International 2013 10.1038/ki.2013.192
2. Uchino S., Kellum J. A., Bellomo R., Doig G. S., Morimatsu H., Morgera S., Schetz M., Tan I., Bouman C., Macedo E., Gibney N., Tolwani A., Ronco C., Acute renal failure in critically ill patients: a multinational, multicenter study. Journal of the American Medical Association 2005 294 7 813 (Pubitemid 41175724)
3. Chawla L. S., Kimmel P. L., Acute kidney injury and chronic kidney disease: an integrated clinical syndrome. Kidney International 2012 82 5 516 524 10.1038/ki.2012.208
4. Bertelli A. A. A., Das D. K., Grapes, wines, resveratrol, and heart health. Journal of Cardiovascular Pharmacology 2009 54 6 468 476 2-s2.0-74949098826 10.1097/FJC.0b013e3181bfaff3
5. Renaud S., de Lorgeril M., Wine, alcohol, platelets, and the French paradox for coronary heart disease. The Lancet 1992 339 8808 1523 1526 2-s2.0-0026651085 10.1016/0140-6736(92)91277-F
6. Catalgol B., Batirel S., Taga Y., Ozer N. K., Resveratrol: French paradox revisited. Frontiers in pharmacology 2012 3, article 141 10.3389/fphar.2012. 00141
7. Fontana L., Partridge L., Longo V. D., Extending healthy life span-from yeast to humans. Science 2010 328 5976 321 326 2-s2.0-77951176737 10.1126/science.1172539
8. Cohen H. Y., Miller C., Bitterman K. J., Wall N. R., Hekking B., Kessler B., Howitz K. T., Gorospe M., de Cabo R., Sinclair D. A., Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 2004 305 5682 390 392 2-s2.0-3142740860 10.1126/science.1099196 (Pubitemid 38938153)
9. Guarente L., Sirtuins, aging, and medicine. The New England Journal of Medicine 2011 364 23 2235 2244 2-s2.0-79958206937 10.1056/NEJMra1100831
10. Kitada M., Kume S., Takeda-Watanabe A., Kanasaki K., Koya D., Sirtuins and renal diseases: relationship with aging and diabetic nephropathy. Clinical Science 2013 124 3 153 164 10.1042/CS20120190
11. Howitz K. T., Bitterman K. J., Cohen H. Y., Lamming D. W., Lavu S., Wood J. G., Zipkin R. E., Chung P., Kisielewski A., Zhang L.-L., Scherer B., Sinclair D. A., Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003 425 6954 191 196 2-s2.0-0141719702 10.1038/nature01960 (Pubitemid 37150899)
12. Kitada M., Kume S., Kanasaki K., Sirtuins as possible drug targets in type 2 diabetes. Current Drug Targets 2013 14 6 622 636 10.2174/ 1389450111314060002
13. Dröge W., Free radicals in the physiological control of cell function. Physiological Reviews 2002 82 1 47 95 2-s2.0-0036086130 (Pubitemid 34654215)
14. Droge W., Roach C. R., Wagner D. P., Hackett H. P., Oxidative stress and aging. Hypoxia 2003 543 191 200 Advances in Experimental Medicine and Biology 10.1007/978-1-4419-8997-0-14 (Pubitemid 38183725)
15. Holthoff J. H., Woodling K. A., Doerge D. R., Burns S. T., Hinson J. A., Mayeux P. R., Resveratrol, a dietary polyphenolic phytoalexin, is a functional scavenger of peroxynitrite. Biochemical Pharmacology 2010 80 8 1260 1265 2-s2.0-77956228179 10.1016/j.bcp.2010.06.027
16. Leonard S. S., Xia C., Jiang B.-H., Stinefelt B., Klandorf H., Harris G. K., Shi X., Resveratrol scavenges reactive oxygen species and effects radical-induced cellular responses. Biochemical and Biophysical Research Communications 2003 309 4 1017 1026 2-s2.0-0141788133 10.1016/j.bbrc.2003.08.105 (Pubitemid 37122632)
17. Pervaiz S., Holme A. L., Resveratrol: its biologic targets and functional activity. Antioxidants and Redox Signaling 2009 11 11 2851 2897 2-s2.0-73449100838 10.1089/ars.2008.2412
18. Robb E. L., Winkelmolen L., Visanji N., Brotchie J., Stuart J. A., Dietary resveratrol administration increases MnSOD expression and activity in mouse brain. Biochemical and Biophysical Research Communications 2008 372 1 254 259 2-s2.0-46549083994 10.1016/j.bbrc.2008.05.028
19. Mokni M., Elkahoui S., Limam F., Amri M., Aouani E., Effect of resveratrol on antioxidant enzyme activities in the brain of healthy rat. Neurochemical Research 2007 32 6 981 987 2-s2.0-34248146970 10.1007/s11064-006- 9255-z (Pubitemid 46726017)
20. Kitada M., Kume S., Imaizumi N., Koya D., Resveratrol improves oxidative stress and protects against diabetic nephropathy through normalization of Mn-SOD dysfunction in AMPK/SIRT1- independent pathway. Diabetes 2011 60 2 634 643 2-s2.0-79551601710 10.2337/db10-0386
21. Colman R. J., Anderson R. M., Johnson S. C., Kastman E. K., Kosmatka K. J., Beasley T. M., Allison D. B., Cruzen C., Simmons H. A., Kemnitz J. W., Weindruch R., Caloric restriction delays disease onset and mortality in rhesus monkeys. Science 2009 325 5937 201 204 2-s2.0-67650439330 10.1126/science. 1173635
22. Fontana L., Meyer T. E., Klein S., Holloszy J. O., Long-term calorie restriction is highly effective in reducing the risk for atherosclerosis in humans. Proceedings of the National Academy of Sciences of the United States of America 2004 101 17 6659 6663 2-s2.0-2342647592 10.1073/pnas.0308291101 (Pubitemid 38586030)
23. Meyer T. E., Kovács S. J., Ehsani A. A., Klein S., Holloszy J. O., Fontana L., Long-term caloric restriction ameliorates the decline in diastolic function in humans. Journal of the American College of Cardiology 2006 47 2 398 402 2-s2.0-30344435943 10.1016/j.jacc.2005.08.069 (Pubitemid 43063261)
24. Imai S.-I., Armstrong C. M., Kaeberlein M., Guarente L., Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 2000 403 6771 795 800 2-s2.0-0034677535 10.1038/35001622 (Pubitemid 30111843)
25. Bordone L., Cohen D., Robinson A., Motta M. C., van Veen E., Czopik A., Steele A. D., Crowe H., Marmor S., Luo J., Gu W., Guarente L., SIRT1 transgenic mice show phenotypes resembling calorie restriction. Aging Cell 2007 6 6 759 767 2-s2.0-36248975293 10.1111/j.1474-9726.2007.00335.x (Pubitemid 350131044)
26. Bellot G., Garcia-Medina R., Gounon P., Chiche J., Roux D., Pouysségur J., Mazure N. M., Hypoxia-induced autophagy is mediated through hypoxia-inducible factor induction of BNIP3 and BNIP3L via their BH3 domains. Molecular and Cellular Biology 2009 29 10 2570 2581 2-s2.0-66349121718 10.1128/MCB.00166-09
27. Steinberg G. R., Kemp B. E., AMPK in health and disease. Physiological Reviews 2009 89 3 1025 1078 2-s2.0-67650914230 10.1152/physrev.00011.2008
28. Park S.-J., Ahmad F., Philp A., Baar K., Williams T., Luo H., Ke H., Rehmann H., Taussig R., Brown A. L., Kim M. K., Beaven M. A., Burgin A. B., Manganiello V., Chung J. H., Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 2012 148 3 421 433 2-s2.0-84856693544 10.1016/j.cell.2012.01.017
29. Price N. L., Gomes A. P., Ling A. J. Y., Duarte F. V., Martin-Montalvo A., North B. J., Agarwal B., Ye L., Ramadori G., Teodoro J. S., Hubbard B. P., Varela A. T., Davis J. G., Varamini B., Hafner A., Moaddel R., Rolo A. P., Coppari R., Palmeira C. M., de Cabo R., Baur J. A., Sinclair D. A., SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metabolism 2012 15 5 675 690 2-s2.0-84860477354 10.1016/j.cmet.2012.04.003
30. Hubbard B. P., Gomes A. P., Dai H., Evidence for a common mechanism of SIRT1 regulation by allosteric activators. Science 2013 339 6124 1216 1219 10.1126/science.1231097
31. Kitada M., Zhang Z., Mima A., King G. L., Molecular mechanisms of diabetic vascular complications. Journal of Diabetes Investigation 2010 1 3 77 89 2-s2.0-79953764336 10.1111/j.2040-1124.2010.00018.x
32. Sharma S., Anjaneyulu M., Kulkarni S. K., Chopra K., Resveratrol, a polyphenolic phytoalexin, attenuates diabetic nephropathy in rats. Pharmacology 2006 76 2 69 75 2-s2.0-31144447091 10.1159/000089720 (Pubitemid 43131538)
33. Palsamy P., Subramanian S., Resveratrol protects diabetic kidney by attenuating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines via Nrf2-Keap1 signaling. Biochimica et Biophysica Acta 2011 1812 7 719 731 2-s2.0-79955634116 10.1016/j.bbadis.2011.03.008
34. Kim M. Y., Lim J. H., Youn H. H., Resveratrol prevents renal lipotoxicity and inhibits mesangial cell glucotoxicity in a manner dependent on the AMPK-SIRT1-PGC1 α axis in db/db mice. Diabetologia 2013 56 1 204 217 10.1007/s00125-012-2747-2
35. Zhang L., Pang S., Deng B., Qian L., Chen J., Zou J., Zheng J., Yang L., Zhang C., Chen X., Liu Z., Le Y., High glucose induces renal mesangial cell proliferation and fibronectin expression through JNK/NF- B/NADPH oxidase/ROS pathway, which is inhibited by resveratrol. International Journal of Biochemistry and Cell Biology 2012 44 4 629 638 2-s2.0-84857918130 10.1016/j.biocel.2012.01.001
36. Ding D.-F., You N., Wu X.-M., Xu J.-R., Hu A.-P., Ye X.-L., Zhu Q., Jiang X.-Q., Miao H., Liu C., Lu Y.-B., Resveratrol attenuates renal hypertrophy in early-stage diabetes by activating AMPK. American Journal of Nephrology 2010 31 4 363 374 2-s2.0-77949552845 10.1159/000300388
37. Lee M.-J., Feliers D., Sataranatarajan K., Mariappan M. M., Li M., Barnes J. L., Choudhury G. G., Kasinath B. S., Resveratrol ameliorates high glucose-induced protein synthesis in glomerular epithelial cells. Cellular Signalling 2010 22 1 65 70 2-s2.0-70350043289 10.1016/j.cellsig.2009.09.011
38. Tikoo K., Singh K., Kabra D., Sharma V., Gaikwad A., Change in histone H3 phosphorylation, MAP kinase p38, SIR 2 and p53 expression by resveratrol in preventing streptozotocin induced type I diabetic nephropathy. Free Radical Research 2008 42 4 397 404 2-s2.0-48849086013 10.1080/10715760801998646
39. Wu L., Zhang Y., Ma X., Zhang N., Qin G., The effect of resveratrol on FoxO1 expression in kidneys of diabetic nephropathy rats. Molecular Biology Reports 2012 39 9 9085 9093 10.1007/s11033-012-1780-z
40. Xu Y., Nie L., Yin Y.-G., Tang J.-L., Zhou J.-Y., Li D.-D., Zhou S.-W., Resveratrol protects against hyperglycemia-induced oxidative damage to mitochondria by activating SIRT1 in rat mesangial cells. Toxicology and Applied Pharmacology 2012 259 3 395 401 2-s2.0-84858018243 10.1016/j.taap.2011.09.028
41. Chen K.-H., Hung C.-C., Hsu H.-H., Jing Y.-H., Yang C.-W., Chen J.-K., Resveratrol ameliorates early diabetic nephropathy associated with suppression of augmented TGF- β /smad and ERK1/2 signaling in streptozotocin-induced diabetic rats. Chemico-Biological Interactions 2011 190 1 45 53 2-s2.0-79952700753 10.1016/j.cbi.2011.01.033
42. Miller R. P., Tadagavadi R. K., Ramesh G., Reeves W. B., Mechanisms of cisplatin nephrotoxicity. Toxins 2010 2 11 2490 2518 2-s2.0-79952142018 10.3390/toxins2112490
43. Do Amaral C. L., Francescato H. D. C., Coimbra T. M., Costa R. S., Darin J. D. C., Antunes L. M. G., Bianchi M. D. L. P., Resveratrol attenuates cisplatin-induced nephrotoxicity in rats. Archives of Toxicology 2008 82 6 363 370 2-s2.0-44449130072 10.1007/s00204-007-0262-x
44. Kim D. H., Jung Y. J., Lee J. E., Lee A. S., Kang K. P., Lee S., Park S. K., Han M. K., Lee S. Y., Ramkumar K. M., Sung M. J., Kim W., Sirt1 activation by resveratrol ameliorates cisplatin-induced renal injury through deacetylation of p53. American Journal of Physiology: Renal Physiology 2011 301 2 F427 F435 2-s2.0-79961143570 10.1152/ajprenal.00258.2010
45. de Jesus Soares T., Volpini R. A., Francescato H. D. C., Costa R. S., da Silva C. G. A., Coimbra T. M., Effects of resveratrol on glycerol-induced renal injury. Life Sciences 2007 81 8 647 656 2-s2.0-34547946389 10.1016/j.lfs.2007. 06.032 (Pubitemid 47268017)
46. Chander V., Chopra K., Protective effect of resveratrol, a polyphenolic phytoalexin on glycerol-induced acute renal failure in rat kidney. Renal Failure 2006 28 2 161 169 2-s2.0-33645543506 10.1080/08860220500531112
47. Morales A. I., Buitrago J. M., Santiago J. M., Fernández-Tagarro M., López-Novoa J. M., Pérez-Barriocanal F., Protective effect of trans-Resveratrol on gentamicin-induced nephrotoxicity. Antioxidants and Redox Signaling 2002 4 6 893 898 2-s2.0-12244306237 (Pubitemid 36042465)
48. Silan C., Uzun Ö., Çomunolu N. Ü., Gokçen S., Bedirhan S., Cengiz M., Gentamicin-induced nephrotoxicity in rats ameliorated and healing effects of resveratrol. Biological and Pharmaceutical Bulletin 2007 30 1 79 83 2-s2.0-33846094030 10.1248/bpb.30.79 (Pubitemid 46066324)
49. Chander V., Tirkey N., Chopra K., Resveratrol, a polyphenolic phytoalexin protects against cyclosporine-induced nephrotoxicity through nitric oxide dependent mechanism. Toxicology 2005 210 1 55 64 2-s2.0-16244405915 10.1016/j.tox.2005.01.011 (Pubitemid 40459642)
50. Yuan Y., Huang S., Wang W., Activation of peroxisome proliferator- activated receptor-gamma coactivator 1alpha ameliorates mitochondrial dysfunction and protects podocytes from aldosterone-induced injury. Kidney International 2012 82 7 771 789 10.1038/ki.2012.188
51. Weight S. C., Bell P. R. F., Nicholson M. L., Renal ischaemia-reperfusion injury. British Journal of Surgery 1996 83 2 162 170 2-s2.0-0030030418 10.1002/bjs.1800830206 (Pubitemid 26050132)
52. Giovannini L., Migliori M., Longoni B. M., Das D. K., Bertelli A. A. E., Panichi V., Filippi C., Bertelli A., Resveratrol, a polyphenol found in wine, reduces ischemia reperfusion injury in rat kidneys. Journal of Cardiovascular Pharmacology 2001 37 3 262 270 2-s2.0-0035127147 10.1097/00005344-200103000- 00004 (Pubitemid 32193504)
53. Chander V., Chopra K., Protective effect of nitric oxide pathway in resveratrol renal ischemia-reperfusion injury in rats. Archives of Medical Research 2006 37 1 19 26 2-s2.0-28444494789 10.1016/j.arcmed.2005.05.018 (Pubitemid 41727886)
54. Xu Q., Hao X., Yang Q., Si L., Resveratrol prevents hyperglycemia-induced endothelial dysfunction via activation of adenosine monophosphate-activated protein kinase. Biochemical and Biophysical Research Communications 2009 388 2 389 394 2-s2.0-69249216358 10.1016/j.bbrc.2009.08.021
55. Arunachalam G., Yao H., Sundar I. K., Caito S., Rahman I., SIRT1 regulates oxidant- and cigarette smoke-induced eNOS acetylation in endothelial cells: role of resveratrol. Biochemical and Biophysical Research Communications 2010 393 1 66 72 2-s2.0-77249158771 10.1016/j.bbrc.2010.01.080
56. Xia N., Strand S., Schlufter F., Role of SIRT1 and FOXO factors in eNOS transcriptional activation by resveratrol. Nitric Oxide 2013 32 29 35 10.1016/j.niox.2013.04.001
57. Heemskerk S., Masereeuw R., Russel F. G. M., Pickkers P., Selective iNOS inhibition for the treatment of sepsis-induced acute kidney injury. Nature Reviews Nephrology 2009 5 11 629 640 2-s2.0-70350575360 10.1038/nrneph.2009.155
58. Mayeur N., Minville V., Jaafar A., Allard J., Al Saati T., Guilbeau-Frugier C., Fourcade O., Girolami J. P., Schaak S., Tack I., Morphologic and functional renal impact of acute kidney injury after prolonged hemorrhagic shock in mice. Critical Care Medicine 2011 39 9 2131 2138 2-s2.0-80051942581 10.1097/CCM.0b013e31821f04f0
59. Wu L., Gokden N., Mayeux P. R., Evidence for the role of reactive nitrogen species in polymicrobial sepsis-induced renal peritubular capillary dysfunction and tubular injury. Journal of the American Society of Nephrology 2007 18 6 1807 1815 2-s2.0-34249884479 10.1681/ASN.2006121402 (Pubitemid 46870317)
60. Wu L., Tiwari M. M., Messer K. J., Holthoff J. H., Gokden N., Brock R. W., Mayeux P. R., Peritubular capillary dysfunction and renal tubular epithelial cell stress following lipopolysaccharide administration in mice. American Journal of Physiology: Renal Physiology 2007 292 1 F261 F268 2-s2.0-33846318159 10.1152/ajprenal.00263.2006 (Pubitemid 46115929)
61. Holthoff J. H., Wang Z., Seely K. A., Gokden N., Mayeux P. R., Resveratrol improves renal microcirculation, protects the tubular epithelium, and prolongs survival in a mouse model of sepsis-induced acute kidney injury. Kidney International 2012 81 4 370 378 2-s2.0-84856410344 10.1038/ki.2011.347
62. Chevalier R. L., Forbes M. S., Thornhill B. A., Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy. Kidney International 2009 75 11 1145 1152 2-s2.0-67349203391 10.1038/ki.2009.86
63. Li J., Qu X., Ricardo S. D., Bertram J. F., Nikolic-Paterson D. J., Resveratrol inhibits renal fibrosis in the obstructed kidney: potential role in deacetylation of Smad3. American Journal of Pathology 2010 177 3 1065 1071 2-s2.0-77956531086 10.2353/ajpath.2010.090923
64. Kume S., Uzu T., Horiike K., Chin-Kanasaki M., Isshiki K., Araki S.-I., Sugimoto T., Haneda M., Kashiwagi A., Koya D., Calorie restriction enhances cell adaptation to hypoxia through Sirt1-dependent mitochondrial autophagy in mouse aged kidney. Journal of Clinical Investigation 2010 120 4 1043 1055 2-s2.0-77951157657 10.1172/JCI41376
65. Inoki K., Mori H., Wang J., Suzuki T., Hong S., Yoshida S., Blattner S. M., Ikenoue T., Rüegg M. A., Hall M. N., Kwiatkowski D. J., Rastaldi M. P., Huber T. B., Kretzler M., Holzman L. B., Wiggins R. C., Guan K.-L., mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. Journal of Clinical Investigation 2011 121 6 2181 2196 2-s2.0-79957927211 10.1172/JCI44771
66. Gödel M., Hartleben B., Herbach N., Liu S., Zschiedrich S., Lu S., Debreczeni-Mór A., Lindenmeyer M. T., Rastaldi M.-P., Hartleben G., Wiech T., Fornoni A., Nelson R. G., Kretzler M., Wanke R., Pavenstädt H., Kerjaschki D., Cohen C. D., Hall M. N., Rüegg M. A., Inoki K., Walz G., Huber T. B., Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. Journal of Clinical Investigation 2011 121 6 2197 2209 2-s2.0-79957881425 10.1172/JCI44774
67. Sakaguchi M., Isono M., Isshiki K., Sugimoto T., Koya D., Kashiwagi A., Inhibition of mTOR signaling with rapamycin attenuates renal hypertrophy in the early diabetic mice. Biochemical and Biophysical Research Communications 2006 340 1 296 301 2-s2.0-29244486472 10.1016/j.bbrc.2005.12.012 (Pubitemid 41827680)
68. Lieberthal W., Levine J. S., Mammalian target of rapamycin and the kidney. II. Pathophysiology and therapeutic implications. American Journal of Physiology: Renal Physiology 2012 303 2 180 191 10.1152/ajprenal.00015.2012
69. Liu M., Wilk S. A., Wang A., Zhou L., Wang R.-H., Ogawa W., Deng C., Dong L. Q., Liu F., Resveratrol inhibits mTOR signaling by promoting the interaction between mTOR and DEPTOR. Journal of Biological Chemistry 2010 285 47 36387 36394 2-s2.0-78449241484 10.1074/jbc.M110.169284